Selskabets formål er at drive handel og industri.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 865.4 mio. | 103.1 mio. | 892.6 mio. | 280.6 mio. | 233 | |
CVR: 16173592
Secondary names: VITALIA A/S, NUTRICARE A/S, DROGEN'S PHARMA A/S
2 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 164 companies in Fremstilling af andre fødevarer i.a.n.
Comparison is based on industry median values
Christian Rykke joined the board
Börje Mats Palmquist joined the board
Shaher Yar Khan left the board
Melis Reidla joined as ADM. DIR.
Karolina Grønås Henriksen left as ADM. DIR.
Christian Rykke left the board
Companies in the same industry and area
CVR 36054573
CVR 45679233
CVR 45469425
CVR 44613530
CVR 41733640
Orkla Care A/S demonstrates a solid financial health with a consistent upward trend in revenue and profit over the past few years. In 2024, the company reported revenue of 865.4 million DKK and a profit of 103.1 million DKK, marking an increase from 837.5 million DKK in revenue and 94.9 million DKK in profit in 2023. Despite a decline in equity from 362.5 million DKK in 2023 to 280.6 million DKK in 2024, the company maintains a healthy profit margin and has shown resilience in its operations within the food manufacturing sector. Key concerns include the significant drop in equity, which may impact future investment capacity, but overall, Orkla Care A/S is well-positioned in its industry with a growing revenue base.
AI-generated summary
companydata.dk